The route of administration does not change the safety or compatibility of the combination
If your TSH drops below 0.3 or your free T4 rises above normal, your levothyroxine dose likely needs reduction
For patients who are tolerating the maximal therapeutic dose of a once-daily or twice-daily GLP-1 receptor agonist (exenatide 10 g twice daily, liraglutide 1.8 mg once daily, or lixisenatide 20 mg once daily) but who are changing to a once-weekly GLP-1 receptor agonist, we recommend starting dulaglutide once weekly or exenatide once weekly at the maximal therapeutic dose (dulaglutide 1.5 mg, exenatide 2 mg)
Retatrutide (research code LY-3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly as a novel triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIP-R), and glucagon receptor (GCG-R)
They may return with a higher proportion of body fat and less muscle than before treatment , increasing the risk of long-term health complications
